Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug(0) Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate. Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More |
FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™. As previously disclosed on April 16, 2012, the Company had Read More |
Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug(0) Company Gets Started on Next Drug in Their Pipeline Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that it has filed a pre-IND submission with the U.S. Food and Drug Administration (FDA) on Prurisol™ (also termed “KM-133″), the Company’s drug in development as a novel treatment for psoriasis. Read More |
Contacts and informationHave an opinion or news that you want to share?
|
Social networks |
Most popular categories |